quinolone - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	quinolone	go back to main search page
Accession:	CHEBI:23765	browse the term
Synonyms:	related_synonym:	quinolones
	alt_id:	MESH:D015363
	xref_mesh:	MESH:D015363

show annotations for term's descendants Sort by:
Rat (340) Mouse (340) Human (352) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (1) Green Monkey (0) Naked Mole-rat (0) All
Genes (340)

quinolone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

[copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased activity of AHR protein; [copper(II) nitrate binds to 5-methyl-1,10-phenanthroline binds to Quinolones] which results in increased activity of AHR protein; resveratrol inhibits the reaction [[copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased activity of AHR protein]; resveratrol inhibits the reaction [[copper(II) nitrate binds to 5-methyl-1,10-phenanthroline binds to Quinolones] which results in increased activity of AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aminolevulinate dehydratase

multiple interactions

Quinolones inhibits the reaction [Nitroprusside results in decreased activity of ALAD protein]

NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474

G

albumin

affects binding

Quinolones analog binds to ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

BCL2 interacting protein 3

multiple interactions
increases expression

[Quinolones co-treated with Oxygen deficiency] results in increased expression of BNIP3 mRNA; Quinolones inhibits the reaction [Mustard Gas inhibits the reaction [Oxygen deficiency results in increased expression of BNIP3 protein]]
Quinolones results in increased expression of BNIP3 mRNA

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

catalase

multiple interactions

Quinolones inhibits the reaction [Nitroprusside results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

decreases expression

Quinolones results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

[copper(II) nitrate binds to 1,10-phenanthroline binds to Quinolones] which results in increased expression of CYP1A1 mRNA; [copper(II) nitrate binds to 5-methyl-1,10-phenanthroline binds to Quinolones] which results in increased expression of CYP1A1 mRNA; [copper(II) nitrate binds to bathophenanthroline binds to Quinolones] which results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

eukaryotic translation initiation factor 4E

multiple interactions

Quinolones inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Quinolones inhibits the reaction [RNA Caps binds to EIF4E protein]

NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

Quinolones inhibits the reaction [Mustard Gas inhibits the reaction [Oxygen deficiency results in increased stability of HIF1A protein]]; Quinolones promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Quinolones results in increased expression of and affects the localization of HIF1A protein

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

Quinolones results in decreased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

thromboxane A synthase 1

decreases activity

Quinolones analog results in decreased activity of TBXAS1 protein

NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096

G

vascular endothelial growth factor A

increases expression
multiple interactions

Quinolones results in increased expression of VEGFA mRNA
[Quinolones co-treated with Oxygen deficiency] results in increased expression of VEGFA mRNA; Quinolones inhibits the reaction [Mustard Gas inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

6-anilino-5,8-quinolinedione

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

6-anilino-5,8-quinolinedione inhibits the reaction [sodium bichromate results in increased ubiquitination of BCL2 protein]
6-anilino-5,8-quinolinedione results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

decreases response to substance

BDNF protein results in decreased susceptibility to 6-anilino-5,8-quinolinedione

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

heat shock protein 90 alpha family class A member 1

multiple interactions

6-anilino-5,8-quinolinedione results in increased expression of and results in increased secretion of HSP90AA1 protein

NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268

G

heat shock protein 90 alpha family class B member 1

increases expression

6-anilino-5,8-quinolinedione results in increased expression of HSP90AB1 protein

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

interleukin 4

decreases secretion

6-anilino-5,8-quinolinedione results in decreased secretion of IL4 protein

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

decreases secretion

6-anilino-5,8-quinolinedione results in decreased secretion of IL5 protein

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions

6-anilino-5,8-quinolinedione inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

vascular endothelial growth factor A

multiple interactions

6-anilino-5,8-quinolinedione inhibits the reaction [heat stable toxin (E coli) results in decreased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

aripiprazole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA dehydrogenase, long chain

decreases expression

Aripiprazole results in decreased expression of ACADL mRNA

NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220

G

adenosine A2a receptor

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

actin related protein 2/3 complex, subunit 1B

decreases expression

Aripiprazole results in decreased expression of ARPC1B mRNA

NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747

G

BCL10, immune signaling adaptor

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of BCL10 mRNA

NCBI chr 2:234,840,880...234,850,520
Ensembl chr 2:234,840,858...234,850,523

G

Bcl2-like 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

BCL6, transcription repressor

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of BCL6 mRNA

NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389

G

BH3 interacting domain death agonist

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of BID mRNA

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

complement C1r

multiple interactions

Aripiprazole promotes the reaction [Ozone results in decreased expression of C1R mRNA]

NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484

G

complement C2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of C2 mRNA

NCBI chr20:3,951,474...3,970,376
Ensembl chr20:3,951,474...3,976,505

G

chromobox 7

decreases expression
increases expression

Aripiprazole results in decreased expression of CBX7 mRNA
Aripiprazole results in increased expression of CBX7 mRNA

NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973

G

C-C motif chemokine ligand 19

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CCL19 mRNA

NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308

G

C-C motif chemokine ligand 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 22

multiple interactions

Aripiprazole inhibits the reaction [Ozone results in increased expression of CCL22 mRNA]

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CCL3 mRNA

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine receptor 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CCR3 mRNA

NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990

G

CD274 molecule

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD33 molecule

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CD33 mRNA

NCBI chr 1:93,935,418...93,940,452
Ensembl chr 1:93,930,971...93,950,149

G

CD44 molecule

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd70 molecule

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CD70 mRNA

NCBI chr 9:2,006,563...2,009,715
Ensembl chr 9:2,006,563...2,009,715

G

CD83 molecule

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CD83 mRNA

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

cadherin 5

multiple interactions

Aripiprazole inhibits the reaction [Ozone results in increased expression of CDH5 mRNA]

NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CCAAT/enhancer binding protein beta

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

carboxylesterase 1D

multiple interactions

Aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of 4-nitrophenyl acetate]; Aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

complement factor B

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

claudin 5

decreases expression

Aripiprazole results in decreased expression of CLDN5 mRNA

NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992

G

cannabinoid receptor 1

increases expression

Aripiprazole results in increased expression of CNR1 mRNA

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

catechol-O-methyltransferase

increases expression

Aripiprazole results in increased expression of COMT mRNA

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cAMP responsive element binding protein 1

increases expression

Aripiprazole results in increased expression of CREB1 mRNA

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cAMP responsive element binding protein 5

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CREB5 mRNA

NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325

G

CREB binding protein

decreases expression

Aripiprazole results in decreased expression of CREBBP mRNA

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

collapsin response mediator protein 1

increases expression

Aripiprazole results in increased expression of CRMP1 mRNA

NCBI chr14:73,509,933...73,556,192
Ensembl chr14:73,509,933...73,556,177

G

colony stimulating factor 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CSF2 mRNA

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CSF3 mRNA

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

C-X3-C motif chemokine ligand 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CX3CL1 mRNA

NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833

G

C-X-C motif chemokine ligand 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CXCL1 mRNA

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CXCL2 mRNA

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CXCL1 mRNA

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 5

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CXCR5 mRNA

NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893

G

C-X-C motif chemokine receptor 6

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CXCR6 mRNA

NCBI chr 8:123,434,417...123,439,568
Ensembl chr 8:123,416,325...123,439,526

G

cytochrome b-245 beta chain

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CYBB mRNA

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

CYLD lysine 63 deubiquitinase

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of CYLD mRNA

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

discoidin domain receptor tyrosine kinase 2

decreases expression

Aripiprazole results in decreased expression of DDR2 mRNA

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

DExD-box helicase 50

increases expression

Aripiprazole results in increased expression of DDX50 mRNA

NCBI chr20:30,561,623...30,591,324
Ensembl chr20:30,560,544...30,591,152

G

dynein, axonemal, light chain 4

decreases expression

Aripiprazole results in decreased expression of DNAL4 mRNA

NCBI chr 7:111,312,424...111,325,283
Ensembl chr 7:111,312,427...111,325,283
Ensembl chr20:111,312,427...111,325,283

G

DNA methyltransferase 3 alpha

increases expression

Aripiprazole results in increased expression of DNMT3A mRNA

NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687

G

dopamine receptor D2

multiple interactions

[Aripiprazole binds to and results in increased activity of DRD2 protein] which results in increased susceptibility to Methamphetamine

PMID:17069544 PMID:17327886

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dual specificity phosphatase 4

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of DUSP4 mRNA

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

dual specificity phosphatase 6

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of DUSP6 mRNA

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

Epstein-Barr virus induced 3

multiple interactions

Aripiprazole promotes the reaction [Ozone results in increased expression of EBI3 mRNA]

NCBI chr 9:774,252...787,544
Ensembl chr 9:783,617...787,544

G

early growth response 1

increases expression

Aripiprazole results in increased expression of EGR1 mRNA; Aripiprazole results in increased expression of EGR1 protein

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

increases expression

Aripiprazole results in increased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

early growth response 4

increases expression

Aripiprazole results in increased expression of EGR4 mRNA

NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328

G

elastase, neutrophil expressed

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of ELANE mRNA

NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100

G

ELAV like RNA binding protein 2

increases expression

Aripiprazole results in increased expression of ELAVL2 mRNA

NCBI chr 5:105,960,872...106,086,463
Ensembl chr 5:105,960,875...106,109,097

G

ETS proto-oncogene 1, transcription factor

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of ETS1 mRNA

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

exocyst complex component 2

increases expression

Aripiprazole results in increased expression of EXOC2 mRNA

NCBI chr17:33,506,289...33,698,246
Ensembl chr17:33,506,338...33,693,289

G

F2R like trypsin receptor 1

multiple interactions

Aripiprazole inhibits the reaction [Ozone results in increased expression of F2RL1 mRNA]

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

fasciculation and elongation protein zeta 1

multiple interactions
increases expression

[Aripiprazole co-treated with Ozone] results in increased expression of FEZ1 mRNA
Aripiprazole results in increased expression of FEZ1 mRNA

NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683

G

fibronectin 1

decreases expression

Aripiprazole results in decreased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

gamma-aminobutyric acid type A receptor subunit beta1

increases expression

Aripiprazole results in increased expression of GABRB1 mRNA

NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948

G

heparin-binding EGF-like growth factor

decreases expression

Aripiprazole results in decreased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

5-hydroxytryptamine receptor 1A

multiple interactions

Aripiprazole binds to and affects the activity of HTR1A protein; Aripiprazole binds to and results in increased activity of HTR1A protein

PMID:17069544 PMID:21823597

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 2A

multiple interactions
decreases response to substance
affects response to substance

Aripiprazole binds to and results in decreased activity of HTR2A protein; Aripiprazole binds to and results in increased activity of HTR2A protein; Aripiprazole inhibits the reaction [Ketanserin binds to HTR2A protein]
HTR2A gene SNP results in decreased susceptibility to Aripiprazole
HTR2A protein affects the susceptibility to Aripiprazole

PMID:16314884 PMID:21823597

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 2C

multiple interactions

Aripiprazole binds to and affects the activity of HTR2C protein

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

intercellular adhesion molecule 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

intercellular adhesion molecule 4, Landsteiner-Wiener blood group

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of ICAM4 mRNA

NCBI chr 8:19,566,075...19,567,171
Ensembl chr 8:19,566,075...19,567,171

G

inducible T-cell co-stimulator ligand

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of ICOSLG mRNA

NCBI chr20:10,600,420...10,610,718
Ensembl chr20:10,600,420...10,610,703

G

interferon beta 1

increases expression
multiple interactions

Aripiprazole results in increased expression of IFNB1 mRNA
Aripiprazole promotes the reaction [Ozone results in increased expression of IFNB1 mRNA]

NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523

G

interferon gamma

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of IFNG mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interferon gamma receptor 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IFNGR1 mRNA

NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785

G

inhibitor of nuclear factor kappa B kinase subunit epsilon

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IKBKE mRNA

NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143

G

interleukin 11

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL11 mRNA

NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129

G

interleukin 1 alpha

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL1R2 mRNA

NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725

G

interleukin 1 receptor accessory protein

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL1RAP mRNA

NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530

G

interleukin 1 receptor accessory protein-like 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL1RAPL2 mRNA

NCBI chr X:100,961,509...102,271,753
Ensembl chr X:100,961,812...102,271,753

G

interleukin 1 receptor-like 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL1RL1 mRNA

NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256

G

interleukin 23 subunit alpha

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 24

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 2 receptor subunit gamma

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of IL2RG mRNA

NCBI chr X:66,395,330...66,399,026
Ensembl chr X:66,392,542...66,399,823

G

interleukin 4 receptor

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL4R mRNA

NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980

G

interleukin 5

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL5 mRNA

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL6 mRNA; Aripiprazole promotes the reaction [Ozone results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 7 receptor

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of IL7R mRNA

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

inositol polyphosphate-5-phosphatase D

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of INPP5D mRNA

NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746

G

interleukin-1 receptor-associated kinase 2

multiple interactions

Aripiprazole promotes the reaction [Ozone results in increased expression of IRAK2 mRNA]

NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602

G

interferon regulatory factor 8

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of IRF8 mRNA

NCBI chr19:48,790,581...48,812,363
Ensembl chr19:48,790,588...48,811,829

G

interferon stimulated exonuclease gene 20

increases expression
multiple interactions

Aripiprazole results in increased expression of ISG20 mRNA
[Aripiprazole co-treated with Ozone] results in increased expression of ISG20 mRNA

NCBI chr 1:132,829,303...132,837,027
Ensembl chr 1:132,815,123...132,837,027

G

integrin subunit alpha 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of ITGA2 mRNA

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha 5

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of ITGA5 mRNA

NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837

G

potassium voltage-gated channel subfamily H member 2

multiple interactions
decreases activity

Aripiprazole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Aripiprazole results in decreased activity of KCNH2 protein

PMID:21158687 PMID:28551711

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 3

increases expression

Aripiprazole results in increased expression of KCNJ3 mRNA

NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124

G

LIF, interleukin 6 family cytokine

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of LIF mRNA

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

leucine rich repeat neuronal 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of LRRN3 mRNA

NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:58,489,010...58,520,330

G

lymphotoxin alpha

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of LTA mRNA

NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859

G

lymphotoxin beta

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of LTB mRNA

NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381

G

LYN proto-oncogene, Src family tyrosine kinase

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of LYN mRNA

NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868

G

monoamine oxidase B

increases expression

Aripiprazole results in increased expression of MAOB mRNA

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

mitogen-activated protein kinase 6

increases expression

Aripiprazole results in increased expression of MAPK6 mRNA

NCBI chr 8:76,146,650...76,169,767
Ensembl chr 8:76,146,690...76,169,720

G

MAPK activated protein kinase 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of MAPKAPK2 mRNA

NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457

G

nuclear factor kappa B subunit 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nuclear factor kappa B subunit 2

multiple interactions

Aripiprazole promotes the reaction [Ozone results in increased expression of NFKB2 mRNA]

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

NFKB inhibitor alpha

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of NFKBIA mRNA

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, pyrin domain containing 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of NLRP3 mRNA

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nucleotide-binding oligomerization domain containing 2

multiple interactions
increases expression

[Aripiprazole co-treated with Ozone] results in increased expression of NOD2 mRNA
Aripiprazole results in increased expression of NOD2 mRNA

NCBI chr19:18,382,369...18,422,817
Ensembl chr19:18,382,439...18,417,177

G

neural proliferation, differentiation and control, 1

decreases expression

Aripiprazole results in decreased expression of NPDC1 mRNA

NCBI chr 3:8,220,446...8,226,446
Ensembl chr 3:8,213,663...8,226,866

G

5' nucleotidase, ecto

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of NT5E mRNA

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

neurotrimin

decreases expression

Aripiprazole results in decreased expression of NTM mRNA

NCBI chr 8:27,376,582...28,366,604
Ensembl chr 8:27,377,773...28,366,595

G

programmed cell death 1 ligand 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of PDCD1LG2 mRNA

NCBI chr 1:227,158,941...227,223,938
Ensembl chr 1:227,158,941...227,223,938

G

platelet derived growth factor C

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of PDGFC mRNA

NCBI chr 2:166,316,870...166,493,449
Ensembl chr 2:166,316,803...166,493,433

G

pyruvate dehydrogenase phosphatase catalytic subunit 1

increases expression

Aripiprazole results in increased expression of PDP1 mRNA

NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217

G

plasminogen activator, urokinase

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of PLAU mRNA

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

plasminogen activator, urokinase receptor

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of PLAUR mRNA

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

POU class 2 homeobox 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of POU2F2 mRNA

NCBI chr 1:80,682,330...80,769,756
Ensembl chr 1:80,685,741...80,724,261

G

proteoglycan 2, pro eosinophil major basic protein

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of PRG2 mRNA

NCBI chr 3:70,062,535...70,066,102
Ensembl chr 3:70,062,535...70,066,101

G

protein kinase cAMP-activated catalytic subunit alpha

increases expression

Aripiprazole results in increased expression of PRKACA protein

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

protein kinase C, delta

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of PRKCD mRNA

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

prolactin

multiple interactions
increases secretion
decreases secretion
decreases expression

Aripiprazole inhibits the reaction [haloperidol decanoate results in increased expression of PRL protein]; Aripiprazole inhibits the reaction [Risperidone results in increased secretion of PRL protein]
Aripiprazole results in increased secretion of PRL protein
Aripiprazole results in decreased secretion of PRL protein
Aripiprazole inhibits the reaction [talipexole results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Aripiprazole results in decreased secretion of PRL protein]
Aripiprazole results in decreased expression of PRL protein

PMID:8613910 PMID:17873694 PMID:19230981 PMID:19519261 PMID:19653986 More...

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

proline dehydrogenase

decreases expression

Aripiprazole results in decreased expression of PRODH mRNA

NCBI chr11:82,910,043...82,927,305
Ensembl chr11:82,910,137...82,927,305

G

proteasome 26S subunit, ATPase 6

increases expression

Aripiprazole results in increased expression of PSMC6 mRNA

NCBI chr15:18,542,585...18,564,057
Ensembl chr15:18,542,563...18,564,055

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

PYD and CARD domain containing

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of PYCARD mRNA

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RAB3A, member RAS oncogene family

increases expression

Aripiprazole results in increased expression of RAB3A mRNA

NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336

G

ras related dexamethasone induced 1

increases expression

Aripiprazole results in increased expression of RASD1 mRNA

NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186

G

RELB proto-oncogene, NF-kB subunit

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of RELB mRNA

NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507

G

RNA sensor RIG-1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of RIGI mRNA

NCBI chr 5:55,321,351...55,369,947
Ensembl chr 5:55,321,235...55,370,819

G

SUMO1 activating enzyme subunit 1

increases expression

Aripiprazole results in increased expression of SAE1 mRNA

NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986

G

strawberry notch homolog 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of SBNO2 mRNA

NCBI chr 7:9,605,572...9,649,529
Ensembl chr 7:9,605,627...9,649,527

G

serpin family B member 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of SERPINB2 mRNA

NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408

G

SH2B adaptor protein 2

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of SH2B2 mRNA

NCBI chr12:20,427,057...20,456,845
Ensembl chr12:20,429,043...20,456,844

G

SLAM family member 6

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of SLAMF6 mRNA

NCBI chr13:84,384,561...84,405,300
Ensembl chr13:84,383,742...84,405,300

G

solute carrier family 6 member 4

affects binding

Aripiprazole binds to SLC6A4 protein

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

solute carrier organic anion transporter family, member 2b1

decreases expression

Aripiprazole results in decreased expression of SLCO2B1 mRNA

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

slit guidance ligand 3

increases expression

Aripiprazole results in increased expression of SLIT3 mRNA

NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634

G

SMAD family member 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of SMAD3 mRNA

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

suppressor of cytokine signaling 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of SOCS1 mRNA

NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383

G

synaptotagmin 17

decreases expression
multiple interactions

Aripiprazole results in decreased expression of SYT17 mRNA
[Aripiprazole co-treated with Ozone] results in decreased expression of SYT17 mRNA

NCBI chr 1:172,695,275...172,761,906
Ensembl chr 1:172,696,120...172,761,960

G

TGF-beta activated kinase 1/MAP3K7 binding protein 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of TAB1 mRNA

NCBI chr 7:111,675,829...111,707,058
Ensembl chr 7:111,686,371...111,707,058

G

tachykinin receptor 3

decreases expression
increases expression

Aripiprazole results in decreased expression of TACR3 mRNA
Aripiprazole results in increased expression of TACR3 mRNA

NCBI chr 2:223,266,536...223,363,791
Ensembl chr 2:223,266,536...223,363,791

G

thrombomodulin

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of THBD mRNA

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

thrombospondin 1

multiple interactions

Aripiprazole inhibits the reaction [Ozone results in increased expression of THBS1 mRNA]

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

TIR domain containing adaptor molecule 1

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of TICAM1 mRNA

NCBI chr 9:1,102,559...1,111,023
Ensembl chr 9:1,102,366...1,123,147

G

toll-like receptor 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of TLR3 mRNA

NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545

G

toll-like receptor 5

increases expression
multiple interactions

Aripiprazole results in increased expression of TLR5 mRNA
[Aripiprazole co-treated with Ozone] results in decreased expression of TLR5 mRNA

NCBI chr13:94,634,778...94,658,992
Ensembl chr13:94,634,801...94,657,738

G

tumor necrosis factor

multiple interactions

Aripiprazole promotes the reaction [Ozone results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF receptor superfamily member 11B

multiple interactions

Aripiprazole inhibits the reaction [Ozone results in increased expression of TNFRSF11B mRNA]

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF receptor superfamily member 12A

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of TNFRSF12A mRNA

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 14

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of TNFRSF14 mRNA

NCBI chr 5:165,486,069...165,494,421
Ensembl chr 5:165,484,262...165,493,703

G

TNF receptor superfamily member 1B

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of TNFRSF1B mRNA

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

G

tumor necrosis factor receptor superfamily, member 22

multiple interactions

Aripiprazole inhibits the reaction [Ozone results in decreased expression of TNFRSF10C mRNA]

NCBI chr 1:198,840,452...198,860,713
Ensembl chr 1:198,840,453...198,856,309

G

TNF receptor superfamily member 8

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of TNFRSF8 mRNA

NCBI chr 5:157,123,183...157,168,421
Ensembl chr 5:157,123,185...157,168,421

G

TNF receptor superfamily member 9

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of TNFRSF9 mRNA

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

TNF superfamily member 10

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 12

multiple interactions

[Aripiprazole co-treated with Ozone] results in decreased expression of TNFSF12 mRNA

NCBI chr10:54,403,870...54,413,213
Ensembl chr10:54,403,870...54,413,213

G

TNF superfamily member 15

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of TNFSF15 mRNA

NCBI chr 5:77,134,885...77,156,171
Ensembl chr 5:77,139,878...77,156,228

G

TNF superfamily member 18

multiple interactions

[Aripiprazole co-treated with Ozone] results in increased expression of TNFSF18 mRNA

NCBI chr13:73,833,478...73,907,249
Ensembl chr13:73,831,252...73,843,169

G

tubulin, beta 2A class IIa

decreases expression

Aripiprazole results in decreased expression of TUBB2A mRNA

NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714

G

vascular endothelial growth factor A

multiple interactions

Aripiprazole promotes the reaction [Ozone results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

WEE1 G2 checkpoint kinase

increases expression

Aripiprazole results in increased expression of WEE1 mRNA

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

G

zinc finger protein 354C

increases expression

Aripiprazole results in increased expression of ZNF354C mRNA

NCBI chr10:35,129,720...35,145,717
Ensembl chr10:35,132,959...35,145,661

carteolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions

Carteolol binds to and results in decreased activity of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

Carteolol binds to and results in decreased activity of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

arrestin, beta 1

increases expression

Carteolol results in increased expression of ARRB1 protein

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

increases expression

Carteolol results in increased expression of ARRB2 protein

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

ATM serine/threonine kinase

multiple interactions
increases expression

Carteolol results in increased expression of and results in increased phosphorylation of ATM protein
Carteolol results in increased expression of ATM mRNA

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

catalase

affects activity

Carteolol affects the activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 27

increases expression

Carteolol results in increased expression of CCL27 mRNA

NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506

G

cyclin-dependent kinase inhibitor 1A

affects expression

Carteolol affects the expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

increases expression

Carteolol results in increased expression of CDKN2A mRNA

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

fumarylacetoacetate hydrolase domain containing 1

affects expression

Carteolol affects the expression of FAHD1 mRNA

NCBI chr10:13,873,539...13,874,978
Ensembl chr10:13,873,527...13,875,012

G

glutathione peroxidase 1

affects activity

Carteolol affects the activity of GPX1 protein

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

H2A.X variant histone

increases phosphorylation

Carteolol results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

hexokinase 2

affects expression

Carteolol affects the expression of HK2 mRNA

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

interleukin 10

increases expression

Carteolol results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

increases expression

Carteolol results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 6

increases expression

Carteolol results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

lamin B1

decreases expression

Carteolol results in decreased expression of LMNB1 protein

NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502

G

microtubule-associated protein 1 light chain 3 beta

affects localization

Carteolol affects the localization of MAP1LC3B protein

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions

Carteolol results in increased expression of and results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Carteolol results in increased expression of and results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

marker of proliferation Ki-67

decreases expression

Carteolol results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

mechanistic target of rapamycin kinase

affects expression

Carteolol affects the expression of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

nicotinamide phosphoribosyltransferase

affects expression

Carteolol affects the expression of NAMPT mRNA

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

NFE2 like bZIP transcription factor 2

affects expression

Carteolol affects the expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

increases expression

Carteolol results in increased expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NADPH oxidase 4

increases expression

Carteolol results in increased expression of NOX4 protein

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

poly (ADP-ribose) polymerase 1

affects expression

Carteolol affects the expression of PARP1 mRNA

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

sirtuin 1

affects expression

Carteolol affects the expression of SIRT1 mRNA

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

superoxide dismutase 1

affects activity

Carteolol affects the activity of SOD1 protein

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

affects activity

Carteolol affects the activity of SOD2 protein

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

transforming growth factor, beta 1

increases expression

Carteolol results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

increases expression

Carteolol results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

affects expression

Carteolol affects the expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

ciprofloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

decreases expression

Ciprofloxacin results in decreased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Ciprofloxacin results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

increases export
multiple interactions
increases expression

ABCC4 protein results in increased export of Ciprofloxacin
[Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin
Ciprofloxacin results in increased expression of ABCC4 mRNA; Ciprofloxacin results in increased expression of ABCC4 protein
[Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin; Gemfibrozil inhibits the reaction [[Ciprofloxacin results in increased expression of ABCC4 protein] which results in decreased uptake of Ciprofloxacin]

PMID:19307362 PMID:22162766

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily G member 2

increases expression

Ciprofloxacin results in increased expression of ABCG2 protein

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

AKT serine/threonine kinase 1

increases phosphorylation

Ciprofloxacin results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 1 family, member A1

increases expression

Ciprofloxacin results in increased expression of ALDH1A1 protein

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases localization
increases expression

BCL2 protein inhibits the reaction [Ciprofloxacin results in increased localization of BAX protein]
Ciprofloxacin results in increased expression of BAX protein

PMID:10741713 PMID:11832715 PMID:11875713 PMID:12632069

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[Etoposide co-treated with Ciprofloxacin] results in decreased expression of BCL2 protein; BCL2 protein inhibits the reaction [Ciprofloxacin results in increased localization of BAX protein]

PMID:11832715 PMID:12063570

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases activity

Ciprofloxacin results in increased cleavage of and results in increased activity of CASP3 protein
Ciprofloxacin results in increased activity of CASP3 protein

PMID:10741713 PMID:11832715 PMID:11875713 PMID:12632069 PMID:30273099

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity

Ciprofloxacin results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity

Ciprofloxacin results in increased activity of CASP9 protein

PMID:11875713 PMID:30273099

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases activity
multiple interactions

Ciprofloxacin results in decreased activity of CAT protein
Quercetin inhibits the reaction [Ciprofloxacin results in decreased activity of CAT protein]

PMID:25902267 PMID:25929518

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolin 1

increases expression

Ciprofloxacin results in increased expression of CAV1 protein

NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705

G

cyclin B1

decreases expression
increases expression

Ciprofloxacin results in decreased expression of CCNB1 protein
Ciprofloxacin results in increased expression of CCNB1 mRNA; Ciprofloxacin results in increased expression of CCNB1 protein

PMID:10741713 PMID:18512786

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin E1

decreases expression

Ciprofloxacin results in decreased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

CD44 molecule

increases expression

Ciprofloxacin results in increased expression of CD44 protein

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

cyclin-dependent kinase 1

increases expression

Ciprofloxacin results in increased expression of CDK1 mRNA; Ciprofloxacin results in increased expression of CDK1 protein

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

decreases phosphorylation

Ciprofloxacin results in decreased phosphorylation of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

decreases expression

Ciprofloxacin results in decreased expression of CDKN1A; Ciprofloxacin results in decreased expression of CDKN1A protein

PMID:10741713 PMID:12063570 PMID:12632069

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CCAAT/enhancer binding protein delta

multiple interactions

Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA]

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

checkpoint kinase 1

increases expression

Ciprofloxacin results in increased expression of CHEK1 protein

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

colony stimulating factor 2

increases expression

Ciprofloxacin results in increased expression of CSF2 protein

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

C-X-C motif chemokine ligand 2

decreases expression

Ciprofloxacin results in decreased expression of CXCL2 protein

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome c, somatic

increases secretion

Ciprofloxacin results in increased secretion of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
decreases activity

[Ciprofloxacin results in decreased activity of CYP1A2 protein] which results in increased abundance of Clozapine; [Ciprofloxacin results in decreased activity of CYP1A2 protein] which results in increased abundance of norclozapine; Ciprofloxacin inhibits the reaction [CYP1A2 protein affects the metabolism of tizanidine]; Ciprofloxacin inhibits the reaction [CYP1A2 protein results in decreased methylation of Caffeine]

PMID:11145498 PMID:11151749 PMID:15592331 PMID:18816299

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, subfamily 2, polypeptide 11

decreases expression

Ciprofloxacin results in decreased expression of CYP2C11 mRNA

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity

Ciprofloxacin results in decreased activity of CYP3A4 protein

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

decreases expression

Ciprofloxacin results in decreased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

dihydroorotate dehydrogenase

multiple interactions
decreases activity

Ciprofloxacin inhibits the reaction [DHODH protein results in increased oxidation of 4,5-dihydroorotic acid]
Ciprofloxacin results in decreased activity of DHODH protein

NCBI chr19:37,551,858...37,573,327
Ensembl chr19:37,558,177...37,591,654

G

fibroblast growth factor 19

decreases expression

Ciprofloxacin results in decreased expression of FGF15 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

glucose-6-phosphate dehydrogenase

increases response to substance

G6PD protein mutant form results in increased susceptibility to Ciprofloxacin

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glutamic-oxaloacetic transaminase 1

increases activity

Ciprofloxacin results in increased activity of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions
increases activity

[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein]
Ciprofloxacin results in increased activity of GPT protein

PMID:29679711 PMID:30273099

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interferon gamma

multiple interactions
decreases expression

Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]
[Ciprofloxacin co-treated with Cyclosporine] results in increased expression of IFNG mRNA; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IFNG protein]]
Ciprofloxacin results in decreased expression of IFNG protein

PMID:16006447 PMID:16968468 PMID:18337667 PMID:19401694

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

Ciprofloxacin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]
Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Mitogens results in increased expression of IL10 protein]]

PMID:16939481 PMID:19401694

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

multiple interactions

Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases expression

Ciprofloxacin affects the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Ciprofloxacin promotes the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP3 protein]
Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]
Ciprofloxacin results in decreased expression of IL1B protein

PMID:9267955 PMID:11052920 PMID:12428247 PMID:16148020 PMID:18197910 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IL2 protein]]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 3

increases expression

Ciprofloxacin results in increased expression of IL3 mRNA; Ciprofloxacin results in increased expression of IL3 protein

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 4

decreases expression

Ciprofloxacin results in decreased expression of IL4 protein

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

multiple interactions

Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA]
Ciprofloxacin inhibits the reaction [irinotecan inhibits the reaction [Mitogens results in increased expression of IL6 protein]]; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of IL6 protein]]

PMID:9267955 PMID:11052920 PMID:19401694

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

potassium voltage-gated channel subfamily H member 2

affects binding

Ciprofloxacin binds to KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

lipocalin 2

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

mitogen activated protein kinase 1

increases phosphorylation

Ciprofloxacin results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation

Ciprofloxacin results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

myoglobin

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

MCL1 apoptosis regulator, BCL2 family member

increases expression

Ciprofloxacin results in increased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

microRNA 133b

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA

NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217

G

microRNA 206

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA

NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332

G

melanocyte inducing transcription factor

decreases expression

Ciprofloxacin results in decreased expression of MITF protein

NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145

G

matrix metallopeptidase 1

multiple interactions
increases expression

Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]
Ciprofloxacin results in increased expression of MMP1 mRNA

PMID:12428247 PMID:16148020

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 13

multiple interactions
decreases expression

Ciprofloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Ciprofloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]
Ciprofloxacin results in decreased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

increases expression
increases activity

Ciprofloxacin results in increased expression of MMP2 mRNA
Ciprofloxacin results in increased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

multiple interactions
increases expression

Ciprofloxacin promotes the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Ciprofloxacin promotes the reaction [IL1B protein results in increased secretion of MMP3 protein]
Ciprofloxacin results in increased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

increases activity
increases expression

Ciprofloxacin results in increased activity of MMP9 protein
Ciprofloxacin results in increased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

Ciprofloxacin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

Nanog homeobox

increases expression

Ciprofloxacin results in increased expression of NANOG protein

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116

G

nucleotide-binding oligomerization domain containing 2

decreases response to substance

NOD2 gene SNP results in decreased susceptibility to Ciprofloxacin

NCBI chr19:18,382,369...18,422,817
Ensembl chr19:18,382,439...18,417,177

G

nuclear receptor subfamily 0, group B, member 2

increases expression

Ciprofloxacin results in increased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

poly (ADP-ribose) polymerase 1

increases cleavage

Ciprofloxacin results in increased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphogluconate dehydrogenase

decreases activity

Ciprofloxacin results in decreased activity of PGD protein

NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778

G

polo-like kinase 1

increases expression

Ciprofloxacin results in increased expression of PLK1 protein

NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400

G

paraoxonase 1

decreases activity

Ciprofloxacin results in decreased activity of PON1 protein

PMID:16880604 PMID:31581362

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

POU class 5 homeobox 1

increases expression

Ciprofloxacin results in increased expression of POU5F1 protein

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

prominin 1

increases expression

Ciprofloxacin results in increased expression of PROM1 protein

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

RT1 class Ia, locus A2

affects expression

Ciprofloxacin affects the expression of HLA-E mRNA

NCBI chr20:4,870,939...4,910,183

G

RT1 class II, locus Db1

affects expression

Ciprofloxacin affects the expression of HLA-DRB1 mRNA

NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258

G

RT1 class Ib, locus M3, gene 1

affects expression

Ciprofloxacin affects the expression of HLA-G mRNA

NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117

G

solute carrier family 2 member 1

affects localization
decreases expression

Ciprofloxacin affects the localization of SLC2A1 mRNA
Ciprofloxacin results in decreased expression of SLC2A1 mRNA

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

SLC51 subunit beta

decreases expression

Ciprofloxacin results in decreased expression of SLC51B mRNA

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier organic anion transporter family member 1B2

increases expression

Ciprofloxacin results in increased expression of SLCO1B2 mRNA

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

snail family transcriptional repressor 1

decreases expression

Ciprofloxacin results in decreased expression of SNAI1 protein

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

snail family transcriptional repressor 2

decreases expression

Ciprofloxacin results in decreased expression of SNAI2 protein

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

SRY-box transcription factor 2

decreases expression

Ciprofloxacin results in decreased expression of SOX2 protein

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

transforming growth factor, beta 1

increases expression
multiple interactions

Ciprofloxacin results in increased expression of TGFB1 mRNA
[Ciprofloxacin co-treated with Cyclosporine] results in decreased expression of TGFB1 mRNA

PMID:18337667 PMID:19371339

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions
decreases expression

Ciprofloxacin affects the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased activity of CEBPD mRNA]; Ciprofloxacin inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of IL6 mRNA]; Ciprofloxacin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Ciprofloxacin promotes the reaction [[IL1B protein co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]
[Ciprofloxacin co-treated with Cyclosporine] results in decreased expression of TNF mRNA; [irinotecan co-treated with Ciprofloxacin] promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Ciprofloxacin inhibits the reaction [irinotecan promotes the reaction [Mitogens results in increased expression of TNF protein]]
Ciprofloxacin results in decreased expression of TNF protein

PMID:9267955 PMID:11052920 PMID:16939481 PMID:16968468 PMID:18197910 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

DNA topoisomerase I

multiple interactions

[Ciprofloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein

NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623

G

DNA topoisomerase II alpha

affects binding
multiple interactions

Ciprofloxacin binds to TOP2A protein
[Ciprofloxacin binds to TOP2A protein] inhibits the reaction [Etoposide binds to TOP2A protein]; [Ciprofloxacin binds to TOP2A protein] inhibits the reaction [F14512 binds to TOP2A protein]

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

xin actin-binding repeat containing 1

multiple interactions

[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA

NCBI chr 8:119,744,778...119,757,547
Ensembl chr 8:119,747,419...119,757,349

difloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

difloxacin binds to KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

elvitegravir

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 1 family, member A2

decreases expression

elvitegravir results in decreased expression of ALDH1A2 mRNA

NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107

G

fibroblast growth factor 8

increases expression

elvitegravir results in increased expression of FGF8 mRNA

NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359

enrofloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

multiple interactions
decreases activity

Selenium inhibits the reaction [enrofloxacin results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

potassium voltage-gated channel subfamily H member 2

affects binding

Enrofloxacin binds to KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

gatifloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glucagon

increases secretion
increases expression
multiple interactions

gatifloxacin results in increased secretion of GCG protein
gatifloxacin results in increased expression of GCG protein
[gatifloxacin co-treated with GCG protein] affects the secretion of INS1 protein; GCG protein affects the reaction [gatifloxacin results in decreased expression of INS2 mRNA]; GCG protein promotes the reaction [gatifloxacin affects the expression of GCGR mRNA]
Diazoxide inhibits the reaction [gatifloxacin results in increased secretion of GCG protein]
gatifloxacin results in increased expression of GCG mRNA

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

glucagon receptor

multiple interactions
affects expression

GCG protein promotes the reaction [gatifloxacin affects the expression of GCGR mRNA]

NCBI chr10:105,808,474...105,816,641
Ensembl chr10:105,808,473...105,816,640

G

insulin 1

multiple interactions
affects secretion

[Gatifloxacin co-treated with GCG protein] affects the secretion of INS1 protein
Gatifloxacin affects the secretion of INS1 protein

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions
decreases expression

GCG protein affects the reaction [gatifloxacin results in decreased expression of INS2 mRNA]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

[Gatifloxacin binds to and results in decreased activity of KCNH2 protein] which results in decreased export of Potassium; Gatifloxacin binds to and results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

matrix metallopeptidase 2

increases expression
increases activity

Gatifloxacin results in increased expression of MMP2 mRNA
Gatifloxacin results in increased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression
increases activity

Gatifloxacin results in increased expression of MMP9 mRNA
Gatifloxacin results in increased activity of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

proprotein convertase subtilisin/kexin type 1

increases expression

gatifloxacin results in increased expression of PCSK1 mRNA

NCBI chr 2:4,395,543...4,442,434
Ensembl chr 2:4,395,543...4,442,434

indacaterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 2

increases activity

indacaterol results in increased activity of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

ivacaftor

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases activity
multiple interactions

ivacaftor results in increased activity of ABCB11 protein mutant form
ivacaftor inhibits the reaction [ABCB11 protein mutant form results in decreased transport of Taurocholic Acid]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

CF transmembrane conductance regulator

multiple interactions
increases activity

[ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; [ivacaftor results in increased activity of CFTR protein mutant form] which affects the transport of Sodium; [ivacaftor results in increased activity of CFTR protein mutant form] which results in increased secretion of Chlorides; ivacaftor inhibits the reaction [Vehicle Emissions results in decreased activity of CFTR protein]
ivacaftor results in increased activity of CFTR protein; ivacaftor results in increased activity of CFTR protein mutant form

PMID:19846789 PMID:21083385 PMID:21602569 PMID:32374624 PMID:34601066

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

lomefloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

lomefloxacin binds to KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

matrix metallopeptidase 2

increases expression
increases activity

lomefloxacin results in increased expression of MMP2 mRNA
lomefloxacin results in increased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression
increases activity

lomefloxacin results in increased expression of MMP9 mRNA
lomefloxacin results in increased activity of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

moxifloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interferon gamma

decreases expression

moxifloxacin results in decreased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

decreases secretion

moxifloxacin results in decreased secretion of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

decreases expression

moxifloxacin results in decreased expression of IL4 protein

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

potassium voltage-gated channel subfamily H member 2

decreases activity

moxifloxacin results in decreased activity of KCNH2 protein

PMID:24052561 PMID:27553911

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

mitogen activated protein kinase 1

decreases phosphorylation

moxifloxacin results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation

moxifloxacin results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

increases secretion
decreases secretion

Moxifloxacin results in increased secretion of MMP1 protein
Moxifloxacin results in decreased secretion of MMP1 protein

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 2

increases activity
increases expression

Moxifloxacin results in increased activity of MMP2 protein
Moxifloxacin results in increased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

decreases secretion
increases secretion

Moxifloxacin results in decreased secretion of MMP3 protein
Moxifloxacin results in increased secretion of MMP3 protein

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

decreases secretion
increases expression
increases activity

Moxifloxacin results in decreased secretion of MMP9 protein
Moxifloxacin results in increased expression of MMP9 mRNA
Moxifloxacin results in increased activity of MMP9 protein

PMID:21058936 PMID:24890593

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

paraoxonase 1

decreases activity

Moxifloxacin results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

RELA proto-oncogene, NF-kB subunit

decreases expression

moxifloxacin results in decreased expression of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

decreases secretion

moxifloxacin results in decreased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

DNA topoisomerase I

multiple interactions

[moxifloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein

NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

UGT1A1 protein results in increased glucuronidation of moxifloxacin

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

UGT1A3 protein results in increased glucuronidation of moxifloxacin

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation

UGT1A9 protein results in increased glucuronidation of moxifloxacin

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

norfloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptosis inducing factor, mitochondria associated 1

increases expression

Norfloxacin results in increased expression of AIFM1 protein

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

BCL2-associated agonist of cell death

increases expression

Norfloxacin results in increased expression of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

increases expression

Norfloxacin results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Norfloxacin results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 2

affects activity

Norfloxacin affects the activity of CASP2 protein

NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379

G

caspase 8

affects activity

Norfloxacin affects the activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects binding
multiple interactions

Norfloxacin binds to CYP1A2 protein
Norfloxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

interleukin 1 beta

multiple interactions

Norfloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Norfloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; Norfloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Norfloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]
[biphenylylacetic acid co-treated with Norfloxacin] results in increased expression of IL1B mRNA; [biphenylylacetic acid co-treated with Norfloxacin] results in increased expression of IL1B protein

PMID:16148020 PMID:16824509

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

potassium voltage-gated channel subfamily H member 2

affects binding

Norfloxacin binds to KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

matrix metallopeptidase 1

multiple interactions

Norfloxacin promotes the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Norfloxacin promotes the reaction [IL1B protein results in increased secretion of MMP1 protein]

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 13

multiple interactions
decreases expression

Norfloxacin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Norfloxacin inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]
Norfloxacin results in decreased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 2

increases activity
increases expression

Norfloxacin results in increased activity of MMP2 protein
Norfloxacin results in increased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression
increases activity

Norfloxacin results in increased expression of MMP9 mRNA
Norfloxacin results in increased activity of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

major histocompatibility complex, class I-related

affects expression

Norfloxacin affects the expression of MR1 mRNA

NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970

G

solute carrier family 22 member 2

multiple interactions

Norfloxacin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

pefloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

increases expression

Pefloxacin metabolite results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Pefloxacin metabolite results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions

Pefloxacin metabolite results in decreased cleavage of and results in increased expression of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cytochrome c, somatic

increases secretion

Pefloxacin metabolite results in increased secretion of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

interleukin 6

decreases expression

Pefloxacin metabolite results in decreased expression of IL6 mRNA; Pefloxacin results in decreased expression of IL6 mRNA; Pefloxacin results in decreased expression of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

potassium voltage-gated channel subfamily H member 2

affects binding

Pefloxacin binds to KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

nitric oxide synthase 2

decreases expression

Pefloxacin metabolite results in decreased expression of INOS mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

tumor necrosis factor

decreases expression

Pefloxacin metabolite results in decreased expression of TNF mRNA; Pefloxacin results in decreased expression of TNF mRNA; Pefloxacin results in decreased expression of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

quinolin-2(1H)-one

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

paraoxonase 1

multiple interactions

2-hydroxyquinoline inhibits the reaction [PON1 protein results in increased hydrolysis of Isoflurophate]; 2-hydroxyquinoline inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

sparfloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

matrix metallopeptidase 2

increases activity
increases expression

sparfloxacin results in increased activity of MMP2 protein
sparfloxacin results in increased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases activity
increases expression

sparfloxacin results in increased activity of MMP9 protein
sparfloxacin results in increased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

streptonigrin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases response to substance

[Dicumarol results in decreased activity of NQO1 protein] which results in decreased susceptibility to Streptonigrin; [Dimethyl Fumarate results in increased activity of NQO1 protein] which results in increased susceptibility to Streptonigrin
NQO1 protein results in increased susceptibility to Streptonigrin

PMID:8615901 PMID:10368308 PMID:15655414

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

tipifarnib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects response to substance

ABCB1 gene SNP affects the susceptibility to tipifarnib

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

AKT serine/threonine kinase 1

multiple interactions

tipifarnib inhibits the reaction [CSF2 protein results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

adaptor related protein complex 1 subunit beta 1

increases expression

tipifarnib results in increased expression of AP1B1 mRNA

NCBI chr14:79,879,482...79,930,778
Ensembl chr14:79,879,533...79,930,778

G

APC regulator of WNT signaling pathway

increases expression

tipifarnib results in increased expression of APC mRNA

NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696

G

bone morphogenetic protein 6

increases expression

tipifarnib results in increased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

caspase 3

multiple interactions

[tipifarnib co-treated with Paclitaxel] results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin D1

multiple interactions

[Tamoxifen co-treated with tipifarnib] results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[Tamoxifen co-treated with tipifarnib] results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

colony stimulating factor 2

multiple interactions
decreases activity

tipifarnib inhibits the reaction [CSF2 protein results in decreased phosphorylation of MAPK1 protein]; tipifarnib inhibits the reaction [CSF2 protein results in decreased phosphorylation of MAPK3 protein]; tipifarnib inhibits the reaction [CSF2 protein results in increased phosphorylation of AKT1 protein]
tipifarnib results in decreased activity of CSF2 protein

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

cytochrome c, somatic

multiple interactions

[tipifarnib co-treated with Paclitaxel] affects the localization of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

fibroblast growth factor 14

increases expression

tipifarnib results in increased expression of FGF14 mRNA

NCBI chr15:101,045,033...101,679,888
Ensembl chr15:101,045,036...101,679,900

G

fibroblast growth factor receptor 2

increases expression

tipifarnib results in increased expression of FGFR2 mRNA

NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626

G

gamma-aminobutyric acid type B receptor subunit 2

increases expression

tipifarnib results in increased expression of GABBR2 mRNA

NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104

G

G protein subunit alpha i2

decreases expression

tipifarnib results in decreased expression of GNAI2 mRNA

NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979

G

HRas proto-oncogene, GTPase

increases response to substance
decreases metabolic processing

HRAS gene mutant form results in increased susceptibility to tipifarnib
tipifarnib results in decreased metabolism of HRAS protein

PMID:15728126 PMID:16403772 PMID:16648579

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

insulin-like growth factor 2

increases expression

tipifarnib results in increased expression of IGF2 mRNA

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

interleukin 18

multiple interactions

geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

tipifarnib inhibits the reaction [[MVK protein mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased secretion of IL1B protein]
geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

Janus kinase 3

increases expression

tipifarnib results in increased expression of JAK3 mRNA

NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536

G

KRAS proto-oncogene, GTPase

increases expression

tipifarnib results in increased expression of KRAS mRNA

NCBI chr 4:178,185,418...178,218,484

G

lysophosphatidic acid receptor 1

increases expression

tipifarnib results in increased expression of LPAR1 mRNA

NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895

G

MAF bZIP transcription factor

increases expression

tipifarnib results in increased expression of MAF mRNA

NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365

G

mitogen-activated protein kinase kinase kinase 1

increases expression

tipifarnib results in increased expression of MAP3K1 mRNA

NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463

G

mitogen activated protein kinase 1

multiple interactions

[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK1 protein; tipifarnib inhibits the reaction [CSF2 protein results in decreased phosphorylation of MAPK1 protein]

PMID:19383813 PMID:22315502

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen-activated protein kinase 12

increases expression

tipifarnib results in increased expression of MAPK12 mRNA

NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664

G

mitogen activated protein kinase 3

multiple interactions

[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK3 protein; tipifarnib inhibits the reaction [CSF2 protein results in decreased phosphorylation of MAPK3 protein]

PMID:19383813 PMID:22315502

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MOS proto-oncogene, serine/threonine kinase

increases expression

tipifarnib results in increased expression of MOS mRNA

NCBI chr 5:16,859,957...16,861,264
Ensembl chr 5:16,859,957...16,861,264

G

muscle RAS oncogene homolog

increases expression

tipifarnib results in increased expression of MRAS mRNA

NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408

G

MAS related GPR family member F

increases expression

tipifarnib results in increased expression of MRGPRF mRNA

NCBI chr 1:200,464,100...200,473,588
Ensembl chr 1:200,463,973...200,473,660

G

mevalonate kinase

multiple interactions

tipifarnib inhibits the reaction [[MVK protein mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased secretion of IL1B protein]; tipifarnib inhibits the reaction [MVK protein mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5]

NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882

G

MYB binding protein 1a

increases expression

tipifarnib results in increased expression of MYBBP1A mRNA

NCBI chr10:57,056,897...57,067,258
Ensembl chr10:57,056,874...57,067,255

G

NDRG family member 2

decreases expression

tipifarnib results in decreased expression of NDRG2 mRNA

NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626

G

NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor

increases expression

tipifarnib results in increased expression of NF2 mRNA

NCBI chr14:79,627,399...79,710,709
Ensembl chr14:79,627,399...79,710,667

G

post-GPI attachment to proteins 2

increases expression

tipifarnib results in increased expression of PGAP2 mRNA

NCBI chr 1:156,591,540...156,618,116
Ensembl chr 1:156,591,615...156,618,114

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma

increases expression

tipifarnib results in increased expression of PIK3C2G mRNA

NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544

G

phospholipase A and acyltransferase 3

increases expression

tipifarnib results in increased expression of PLAAT3 mRNA

NCBI chr 1:204,782,608...204,816,397
Ensembl chr 1:204,782,729...204,817,667

G

protein tyrosine phosphatase, non-receptor type 11

multiple interactions

tipifarnib promotes the reaction [PTPN11 protein mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]

NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925

G

RAB14, member RAS oncogene family

increases expression

tipifarnib results in increased expression of RAB14 mRNA

NCBI chr 3:18,501,953...18,523,253
Ensembl chr 3:18,501,963...18,523,172

G

RAB29, member RAS oncogene family

increases expression

tipifarnib results in increased expression of RAB29 mRNA

NCBI chr13:43,307,757...43,313,420
Ensembl chr13:43,307,775...43,313,417

G

RAB2A, member RAS oncogene family

increases expression

tipifarnib results in increased expression of RAB2 mRNA

NCBI chr 5:21,676,017...21,740,035
Ensembl chr 5:21,676,129...21,739,899

G

RAB38, member RAS oncogene family

increases expression

tipifarnib results in increased expression of RAB38 mRNA

NCBI chr 1:142,182,566...142,262,923
Ensembl chr 1:142,182,556...142,262,924

G

RAB3C, member RAS oncogene family

increases expression

tipifarnib results in increased expression of RAB3C mRNA

NCBI chr 2:41,627,720...41,843,541
Ensembl chr 2:41,627,720...41,843,749

G

RAB8B, member RAS oncogene family

increases expression

tipifarnib results in increased expression of RAB8B mRNA

NCBI chr 8:67,458,921...67,536,466
Ensembl chr 8:67,458,923...67,536,384

G

Raf-1 proto-oncogene, serine/threonine kinase

increases expression

tipifarnib results in increased expression of RAF1 mRNA

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

ral guanine nucleotide dissociation stimulator

decreases expression

tipifarnib results in decreased expression of RALGDS mRNA

NCBI chr 3:11,839,686...11,880,059
Ensembl chr 3:11,839,416...11,880,059

G

regulator of G-protein signaling 8

increases expression

tipifarnib results in increased expression of RGS8 mRNA

NCBI chr13:65,804,703...65,848,955
Ensembl chr13:65,804,797...65,846,807

G

Ras homolog, mTORC1 binding

multiple interactions
decreases activity

[tipifarnib results in decreased activity of RHEB protein] which results in increased susceptibility to Cisplatin

NCBI chr 4:10,278,970...10,320,160
Ensembl chr 4:10,279,370...10,320,160

G

Ras and Rab interactor 1

increases expression

tipifarnib results in increased expression of RIN1 mRNA

NCBI chr 1:202,355,729...202,362,731
Ensembl chr 1:202,355,890...202,362,729

G

Rho-associated coiled-coil containing protein kinase 1

increases expression

tipifarnib results in increased expression of ROCK1 mRNA

NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571

G

Rho-associated coiled-coil containing protein kinase 2

increases expression

tipifarnib results in increased expression of ROCK2 mRNA

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

RRAD, Ras related glycolysis inhibitor and calcium channel regulator

increases expression

tipifarnib results in increased expression of RRAD mRNA

NCBI chr19:354,184...357,424
Ensembl chr19:354,198...357,417

G

transforming growth factor, beta 1

decreases expression

tipifarnib results in decreased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta receptor 2

increases expression

tipifarnib results in increased expression of TGFBR2 mRNA

NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228

G

tumor necrosis factor

multiple interactions

geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

decreases expression

tipifarnib results in decreased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vav guanine nucleotide exchange factor 1

increases expression

tipifarnib results in increased expression of VAV1 mRNA

NCBI chr 9:2,161,985...2,209,951
Ensembl chr 9:2,157,900...2,208,937

G

zinc finger, matrin type 3

increases expression

tipifarnib results in increased expression of ZMAT3 mRNA

NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:115,106,966...115,136,863

vosaroxin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

vosaroxin inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to ARNT protein]]

NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580

G

caspase 3

increases activity

vosaroxin results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
decreases expression

dorsomorphin inhibits the reaction [vosaroxin results in decreased expression of HIF1A protein]; SIRT3 protein inhibits the reaction [vosaroxin results in decreased expression of HIF1A protein]; vosaroxin inhibits the reaction [Oxygen deficiency affects the localization of HIF1A protein]; vosaroxin inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to ARNT protein]]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

isocitrate dehydrogenase (NADP(+)) 2

increases activity
multiple interactions

vosaroxin results in increased activity of IDH2 protein
SIRT2 protein affects the reaction [vosaroxin results in increased activity of IDH2 protein]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

sirtuin 2

multiple interactions

SIRT2 protein affects the reaction [vosaroxin results in increased activity of IDH2 protein]; SIRT2 protein affects the reaction [vosaroxin results in increased activity of SOD2 protein]

NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975

G

sirtuin 3

multiple interactions

SIRT3 protein inhibits the reaction [vosaroxin results in decreased expression of HIF1A protein]

NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808

G

superoxide dismutase 2

increases activity
multiple interactions

vosaroxin results in increased activity of SOD2 protein
SIRT2 protein affects the reaction [vosaroxin results in increased activity of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19867
chemical entity	19865
molecular entity	19865
polyatomic entity	19817
molecule	19707
organic molecule	19692
organic cyclic compound	19482
organic aromatic compound	19346
quinolines	2660
quinolone	340
(+)-Plicamine	0
(1'E,3'E)-5-(3,3-dimethyloxiran-2-yl)-3-methylhexa-1,3-dienyl-quinolinone B	0
(1R,9S,10R,12S,14Z)-1-amino-14-ethylidene-12-methyl-11-oxa-6-azatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3-dien-5-one	0
(E)-1-hydroxy-2-(non-1-en-1-yl)quinolin-4-one	0
1,2,3,4-tetrahydroquinoline-2,4-dione	0
1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid +	0
1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-7-piperidin-4-yl-3,4-dihydroquinolin-2(1H)-one	0
1-Cyclopropyl-4-oxo-5-methyl-6-fluoro-7-[(2-aminoethyl)amino]-1,4-dihydroquinoline-3-carboxylic acid	0
1-Cyclopropyl-4-oxo-5-methyl-6-fluoro-7-[(2-aminopropyl)amino]-1,4-dihydroquinoline-3-carboxylic acid	0
1-allyl-4-hydroxy-2-oxo-N-(1,3-thiazol-2-yl)-1,2-dihydroquinoline-3-carboxamide	0
1-allyl-4-hydroxy-2-oxo-N-(4-phenyl-1,3-thiazol-2-yl)-1,2-dihydroquinoline-3-carboxamide	0
1-butyl-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-hydroxy-2-oxoquinoline-3-carboxamide	0
1-cyclohexyl-5-\{4-[(4-hydroxy-2-oxo-3,4-dihydro-1H-quinolin-6-yl)oxy]butyl\}-4H-1lambda5,2,3,4-tetrazol-1-ylium	0
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-N-[4-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]-1,4-dihydroquinoline-3-carboxamide	0
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-4-sulfopiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid	0
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carbonyloxysulfonic acid	0
1-hydroxy-2-nonylquinolin-4-one	0
2(1H)-Quinolinone, 3-methoxy-	0
2,8-Quinolinediol 2-sulfate	0
2-heptyl-3-hydroxy-4-quinolone	0
2-heptyl-4-quinolone	0
2-hydroxy-4-quinolone-3-carboxylic acid	0
3,4-Quinolinediol, 2-nonyl-	0
3-(5-\{[4-(aminomethyl)piperidin-1-yl]methyl\}-1H-indol-2-yl)quinolin-2(1H)-one	0
3-Methyl-quinolin-2,8-diol	0
3-Methyl-quinolin-2-ol	0
3-[5-(piperidin-1-ylmethyl)-1H-indol-2-yl]-6-(1H-pyrazol-4-yl)quinolin-2(1H)-one	0
3-amino-7-hydroxy-3,4-dihydro-1H-quinolin-2-one	0
3-benzyl-1-butyl-4-hydroxy-1,2-dihydroquinolin-2-one	0
3-benzyl-4-hydroxyquinolin-2(1H)-one	0
3-ethyl-4-hydroxy-1-methyl-1,2-dihydroquinolin-2-one	0
3-farnesyl-3-hydroxy-2-methyl-1-oxo-1lambda(5)-quinolin-4-one	0
3-hydroxy-2-methylquinolin-4(1H)-one	0
3-hydroxyquinolin-4(1H)-one	0
3-methylquinolin-2(1H)-one	0
3-oxociprofloxacin	0
4-hydroxy-1-isobutyl-N-(4-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide	0
4-hydroxy-1-isobutyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide	0
4-hydroxy-1-isopentyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide	0
4-hydroxy-1-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxo-1,2-dihydro-3-quinolinecarboxamide	0
4-hydroxy-2-quinolone	0
4-methylquinolin-2(1H)-one	0
4-quinolone +	0
4-quinolone-3-carboxaldehyde	0
5,6-dihydroxy-3-methyl-5,6-dihydroquinolin-2(1H)-one	0
5,6-dihydroxy-3-methylquinolin-2(1H)-one	0
5,8-Dihydroxy-3,4-dihydrocarbostyril	0
5-hydroxy-3,4-dihydro-2(1h)-quinolinone	0
5-hydroxyquinolin-2(1H)-one	0
6,8-Difluoro-2-methylquinolin-4-ol	0
6-Fluoro-2-methylquinolin-4-ol	0
6-amino-2,3-dimethylquinoline-5,8-dione	0
6-anilino-5,8-quinolinedione	8
6-chloro-4-hydroxy-3-(phenylmethyl)-1H-quinolin-2-one	0
6-chloro-7-[2-(4-morpholinyl)ethylamino]quinoline-5,8-dione	0
6-hydroxy-3-methylquinolin-2(1H)-one	0
6-hydroxyquinolin-2(1H)-one	0
7-chloro-3-[cyclopropyl(oxo)methyl]-4-hydroxy-1H-quinolin-2-one	0
7-hydroxy-4-methyl-1H-quinolin-2-one	0
7-hydroxyquinolin-2(1H)-one	0
8-chloroquinolin-2(1H)-one	0
8-hydroxyquinolin-2(1H)-one	0
8-methylquinolin-2(1H)-one	0
AS1842856	0
Deoxynyboqionone	0
Diazaquinomycin A	0
Diazaquinomycin C	0
Diazaquinomycin E	0
Diazaquinomycin F	0
Diazaquinomycin G	0
Diazaquinomycin H	0
Diazaquinomycin J	0
ELQ-271	0
HPI-1	0
Huptremule C	0
Huptremule D	0
Indacaterol fumarate	0
LSM-1581	0
LSM-5335	0
LSM-5567	0
Lagunamycin	0
Marinoaziridine A	0
Marinoaziridine B	0
Methyl 2,6-dihydroxy-4-quinolinecarboxylate	0
N-methyl-4-hydroxy-2-quinolinone	0
N-methylcorydaldine	0
Ofloxacin methyl ester	0
PF-573228	0
Quinolinediol	0
RSL5	0
SCH 538415	0
Sannanine	0
Selagine	0
abediterol	0
aripiprazole	167
aripiprazole lauroxil	0
aspoquinolone B	0
aurachin C +	0
carteolol	33
ciprofloxacin +	79
difloxacin	1
elvitegravir +	2
enrofloxacin	2
finafloxacin	0
fluquinometoate	0
gatifloxacin +	8
indacaterol	1
ivacaftor +	2
lomefloxacin +	3
moxifloxacin	17
norfloxacin	15
pefloxacin +	8
penigequinolone A	0
penigequinolone B	0
quinolin-2(1H)-one	1
sparfloxacin	2
streptonigrin	1
sulfociprofloxacin	0
thalifolin	0
tipifarnib	57
uranidine	0
vosaroxin	7
yaequinolone C	0
yaequinolone D	0
zavegepant	0
Path 2
Term	Annotations
CHEBI ontology	19867
subatomic particle	19865
composite particle	19865
hadron	19865
baryon	19865
nucleon	19865
atomic nucleus	19865
atom	19865
main group element atom	19803
p-block element atom	19803
carbon group element atom	19744
carbon atom	19740
organic molecular entity	19740
organic molecule	19692
organic cyclic compound	19482
organic heterocyclic compound	18872
organonitrogen heterocyclic compound	18150
quinolines	2660
quinolone	340
(+)-Plicamine	0
(1'E,3'E)-5-(3,3-dimethyloxiran-2-yl)-3-methylhexa-1,3-dienyl-quinolinone B	0
(1R,9S,10R,12S,14Z)-1-amino-14-ethylidene-12-methyl-11-oxa-6-azatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3-dien-5-one	0
(E)-1-hydroxy-2-(non-1-en-1-yl)quinolin-4-one	0
1,2,3,4-tetrahydroquinoline-2,4-dione	0
1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid +	0
1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-7-piperidin-4-yl-3,4-dihydroquinolin-2(1H)-one	0
1-Cyclopropyl-4-oxo-5-methyl-6-fluoro-7-[(2-aminoethyl)amino]-1,4-dihydroquinoline-3-carboxylic acid	0
1-Cyclopropyl-4-oxo-5-methyl-6-fluoro-7-[(2-aminopropyl)amino]-1,4-dihydroquinoline-3-carboxylic acid	0
1-allyl-4-hydroxy-2-oxo-N-(1,3-thiazol-2-yl)-1,2-dihydroquinoline-3-carboxamide	0
1-allyl-4-hydroxy-2-oxo-N-(4-phenyl-1,3-thiazol-2-yl)-1,2-dihydroquinoline-3-carboxamide	0
1-butyl-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-hydroxy-2-oxoquinoline-3-carboxamide	0
1-cyclohexyl-5-\{4-[(4-hydroxy-2-oxo-3,4-dihydro-1H-quinolin-6-yl)oxy]butyl\}-4H-1lambda5,2,3,4-tetrazol-1-ylium	0
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-N-[4-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]-1,4-dihydroquinoline-3-carboxamide	0
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-4-sulfopiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid	0
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carbonyloxysulfonic acid	0
1-hydroxy-2-nonylquinolin-4-one	0
2(1H)-Quinolinone, 3-methoxy-	0
2,8-Quinolinediol 2-sulfate	0
2-heptyl-3-hydroxy-4-quinolone	0
2-heptyl-4-quinolone	0
2-hydroxy-4-quinolone-3-carboxylic acid	0
3,4-Quinolinediol, 2-nonyl-	0
3-(5-\{[4-(aminomethyl)piperidin-1-yl]methyl\}-1H-indol-2-yl)quinolin-2(1H)-one	0
3-Methyl-quinolin-2,8-diol	0
3-Methyl-quinolin-2-ol	0
3-[5-(piperidin-1-ylmethyl)-1H-indol-2-yl]-6-(1H-pyrazol-4-yl)quinolin-2(1H)-one	0
3-amino-7-hydroxy-3,4-dihydro-1H-quinolin-2-one	0
3-benzyl-1-butyl-4-hydroxy-1,2-dihydroquinolin-2-one	0
3-benzyl-4-hydroxyquinolin-2(1H)-one	0
3-ethyl-4-hydroxy-1-methyl-1,2-dihydroquinolin-2-one	0
3-farnesyl-3-hydroxy-2-methyl-1-oxo-1lambda(5)-quinolin-4-one	0
3-hydroxy-2-methylquinolin-4(1H)-one	0
3-hydroxyquinolin-4(1H)-one	0
3-methylquinolin-2(1H)-one	0
3-oxociprofloxacin	0
4-hydroxy-1-isobutyl-N-(4-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide	0
4-hydroxy-1-isobutyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide	0
4-hydroxy-1-isopentyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide	0
4-hydroxy-1-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxo-1,2-dihydro-3-quinolinecarboxamide	0
4-hydroxy-2-quinolone	0
4-methylquinolin-2(1H)-one	0
4-quinolone +	0
4-quinolone-3-carboxaldehyde	0
5,6-dihydroxy-3-methyl-5,6-dihydroquinolin-2(1H)-one	0
5,6-dihydroxy-3-methylquinolin-2(1H)-one	0
5,8-Dihydroxy-3,4-dihydrocarbostyril	0
5-hydroxy-3,4-dihydro-2(1h)-quinolinone	0
5-hydroxyquinolin-2(1H)-one	0
6,8-Difluoro-2-methylquinolin-4-ol	0
6-Fluoro-2-methylquinolin-4-ol	0
6-amino-2,3-dimethylquinoline-5,8-dione	0
6-anilino-5,8-quinolinedione	8
6-chloro-4-hydroxy-3-(phenylmethyl)-1H-quinolin-2-one	0
6-chloro-7-[2-(4-morpholinyl)ethylamino]quinoline-5,8-dione	0
6-hydroxy-3-methylquinolin-2(1H)-one	0
6-hydroxyquinolin-2(1H)-one	0
7-chloro-3-[cyclopropyl(oxo)methyl]-4-hydroxy-1H-quinolin-2-one	0
7-hydroxy-4-methyl-1H-quinolin-2-one	0
7-hydroxyquinolin-2(1H)-one	0
8-chloroquinolin-2(1H)-one	0
8-hydroxyquinolin-2(1H)-one	0
8-methylquinolin-2(1H)-one	0
AS1842856	0
Deoxynyboqionone	0
Diazaquinomycin A	0
Diazaquinomycin C	0
Diazaquinomycin E	0
Diazaquinomycin F	0
Diazaquinomycin G	0
Diazaquinomycin H	0
Diazaquinomycin J	0
ELQ-271	0
HPI-1	0
Huptremule C	0
Huptremule D	0
Indacaterol fumarate	0
LSM-1581	0
LSM-5335	0
LSM-5567	0
Lagunamycin	0
Marinoaziridine A	0
Marinoaziridine B	0
Methyl 2,6-dihydroxy-4-quinolinecarboxylate	0
N-methyl-4-hydroxy-2-quinolinone	0
N-methylcorydaldine	0
Ofloxacin methyl ester	0
PF-573228	0
Quinolinediol	0
RSL5	0
SCH 538415	0
Sannanine	0
Selagine	0
abediterol	0
aripiprazole	167
aripiprazole lauroxil	0
aspoquinolone B	0
aurachin C +	0
carteolol	33
ciprofloxacin +	79
difloxacin	1
elvitegravir +	2
enrofloxacin	2
finafloxacin	0
fluquinometoate	0
gatifloxacin +	8
indacaterol	1
ivacaftor +	2
lomefloxacin +	3
moxifloxacin	17
norfloxacin	15
pefloxacin +	8
penigequinolone A	0
penigequinolone B	0
quinolin-2(1H)-one	1
sparfloxacin	2
streptonigrin	1
sulfociprofloxacin	0
thalifolin	0
tipifarnib	57
uranidine	0
vosaroxin	7
yaequinolone C	0
yaequinolone D	0
zavegepant	0

paths to the root